MUC1 and idiopathic pulmonary fibrosis: The findings of our study highlight the heterogeneity of patients with IPF, identify subgroups of patients who may have a poor response and adverse outcomes despite ongoing nintedanib anti-fibrotic treatment, and further support the clinical utility of blood molecular markers (particularly KL-6) for IPF.